There are concerns that launch of Teva’s migraine drug may be delayed because of issues uncovered by the FDA at a manufacturing plant run by South Korea’s Celltrion.
Life science companies are failing to achieve their full digital potential, particularly when it comes to the use of remote channels for effective physician engagement.
